source
- Eli Lilly's retatrutide shows over a third of patients lose 25%+ weight in phase 3 trialEli Lilly presented detailed results from its phase 3 retatrutide trial at the European Association for the Study of Diabetes meeting in Milan and in a recent Lancet publication. The study enrolle…
- Eli Lilly’s Zepbound plus amylin candidate shows 23% weight loss in phase 2 trial, but many patients stopped treatmentEli Lilly tested a combination of its GLP‑1 obesity drug Zepbound with the amylin‑targeting candidate eloralintide in a mid‑stage study of people with obesity and type 2 diabetes. After 48 weeks,…